Publications by authors named "Sue Xu"

Background: Angina pectoris (AP) is the initial and the most common manifestation of coronary artery disease (CAD). Therefore, management and control of AP can help prevent further complications associated with CAD. However, there is under-reporting of angina symptoms in clinical practice, resulting in under-treatment and reduced quality of life (QoL).

View Article and Find Full Text PDF

Monoclonal antibodies represent important weapons in our arsenal to against the COVID-19 pandemic. However, this potential is severely limited by the time-consuming process of developing effective antibodies and the relative high cost of manufacturing. Herein, we present a rapid and cost-effective lipid nanoparticle (LNP) encapsulated-mRNA platform for in vivo delivery of SARS-CoV-2 neutralization antibodies.

View Article and Find Full Text PDF

Cytoglobin (Cygb), a member of the hexacoordinate globin superfamily (hxHb), is expressed in fibroblasts from a broad range of tissues. The physiological functions of hxHb are still unclear, but biochemical studies reveal that they can scavenge toxic species, such as nitric oxide, peroxynitrite, and hydrogen peroxide. We demonstrate that the overexpression of Cygb in rat hepatic stellate cells, both in vitro and in vivo, protects against oxidative stress, inhibiting their differentiation into a myofibroblast-like phenotype.

View Article and Find Full Text PDF

Background: The aim of this study is to provide a basis for the design of appropriate protocols for the shipping and storage of rAAV vectors for experimental laboratory studies and clinical trials.

Material/methods: rAAV stocks were generated by standard methods and then subjected to different environments. The transduction efficiency of viral vectors both in vitro and in vivo was determined by luciferase activity and immunohistochemistry.

View Article and Find Full Text PDF
Article Synopsis
  • Liver cancer has a poor prognosis and there are limited effective treatments available.
  • Researchers previously showed that injecting a specific viral particle (AAV) expressing angiostatin can help suppress tumor growth in the liver.
  • In this study, they combined angiostatin therapy with a type of immunotherapy using a virus that stimulates immune response (AAV-B7.1), which improved tumor rejection and increased survival rates in mice with advanced liver cancer.
View Article and Find Full Text PDF

The hepatitis B virus (HBV) infection is a public health problem worldwide, particularly in East Asia. The current therapy of HBV infection is mostly based on chemical agents and cytokines that have been shown to provide limited efficacy and are also toxic to the human body. Gene therapy is a new therapeutic strategy against HBV infection, involving the transmission of gene drugs into liver cells by specific delivery systems and methods.

View Article and Find Full Text PDF

Metastatic liver cancer has a very poor prognosis and lacks effective therapy. Anti-angiogenic therapies, which starve tumors of blood supply, have proven to be effective in preclinical models because tumor growth is angiogenesis dependent. However, long-term, high-level, and sustained expression of angiogenesis inhibitors, such as angiostatin, is necessary to prevent dormant tumors from becoming active again.

View Article and Find Full Text PDF